Landscape of current and emerging cell therapy clinical trials in the UK: Current status, comparison to global trends and future perspectives

Regenerative Medicine

Volumn 10, Issue 2, 2015, Pages 169-179

  Bisson, Isabelle ^a   Green, Emma ^a   Sharpe, Michaela ^a   Herbert, Chris ^a   Hyllner, Johan ^a,b   Mount, Natalie ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

ATMP; cell therapy; clinical trial; immunotherapy; regenerative medicine; stem cells; UK

Indexed keywords

BIOLOGICAL THERAPY; CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); FINANCIAL MANAGEMENT; GEOGRAPHY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MULTICENTER STUDY (TOPIC); NEOPLASMS; PROCEDURES; TRENDS; UNITED KINGDOM;

CELL TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; CLINICAL TRIALS AS TOPIC; FINANCING, GOVERNMENT; GEOGRAPHY; GREAT BRITAIN; HUMANS; IMMUNOTHERAPY; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RESEARCH DESIGN;

EID: 84926470092     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.14.71     Document Type: Review

References (28)

1. Alliance for Regenerative Medicine. Regenerative medicine annual industry report. http://alliancerm.org
2. Maciulaitis R, DApote L, Buchanan A, Pioppo L, SchneiDer CK. Clinical Development of adVanced therapy medicinal products in Europe: eviDence that regulators must be proactive. Mol. Ther. 20(3), 479-482 (2012)
3. Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen. Med. 9(1), 27-39 (2014)
4. Culme-Seymour EJ. Global update UK. Regen. Med. 7(Suppl.6), 136-138 (2012)
5. The Rt Hon David Willetts MP. The eight great technologies which will propel the UK to future growth receive a funding boost. Westminster, London, www.gov.uk/government/speeches/eight-great-technologies
6. Luo J, Mathews KRW. Globalization of stem cell science: an examination of current and past collaborative research networks. PLoS ONE 8(9), e73598 (2013)
7. Trounson A, Baum E, Gibbons D, Tekamp-Olson P. Developing a case study moDel for successful translation of stem cell therapies. Cell Stem Cell 6(6), 513-516 (2010)
8. CuenDe N, Izela A. Clinical translation of stem cell therapies: a bridgeable gap. Cell Stem Cell 6(6), 508-512 (2010)
9. Schachter, B. Therapies of the state. Nat. Biotechnol. 32(8), 736-741 (2014)
10. Cell Therapy Catapult. Clinical Trial database and cell therapy catapult pre-clinical research database. https://ct.catapult.org.uk/resources
11. Clinical Trials Gov www. clinicaltrials.gov
12. Maus M, Grupp S, Porter D, June C. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123(17), 2625-2635 (2014)
13. Ruella M, Kalos M. Adoptive Immunotherapy for cancer. Immunol. Rev. 257(1), 14-38 (2014)
14. Becker S, Jayaram H, Limb GA. Recent adVances towards the clinical application of stem cells for retinal regeneration. Cells 1(4), 851-873 (2012)
15. Carr AJ, Smart MJ, RamsDen CM, Powner MB, da Cruz L, Coffey PJ. Development of human embryonic stem cell therapies for age-related macular Degeneration. Trends Neurosci. 36(7), 385-395 (2013)
16. Ahmad S. Concise review: limbal stem cell Deficiency, dysfunction, and distress. Stem Cells Transl. Med. 1(2), 110-115 (2012)
17. Ratcliffe E, Glen KE, Naing MW, Williams DJ. Current status and perspectives on stem cell-based therapies unDergoing clinical trials for regenerative medicine: case studies. Br. Med. Bull. 108, 73-94 (2013)
18. Pearce KF, HilDebrandt M, Greinix H et al. Regulation of adVanced therapy medicinal products in Europe and the role of acaDemia. Cytotherapy 16(3), 289-297 (2014)
19. Annex 1. Summary of production chracteristics. www.ema.europa.eu
20. Gerlier L, Lamotte M, Wille M et al. The cost utility of autologous chondrocytes implantation using ChondroCelect in symptomatic knee cartilage lesions in Belgium. Pharmacoeconomics 28(12), 1129-1146 (2010)
21. European Medicines Agency. Committee for medicinal products for human use. Assessment report. www.ema.europa.eu
22. European Medicine Agency. EPAR summary for the public: Glybera. www.ema.europa.eu
23. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T Immunotherapy for castration-resistant prostate cancer. N. Eng. J. Med. 363(5), 411-422 (2010)
24. European Medicine Agency. EPAR summary for the public: Provenge. www.ema.europa.eu
25. REMEDiE: regenerative medicine in Europe. Emerging Needs and Challenges in a Global Context. Report from REMEDiE Final Conference, Bilbao, Spain, 2011. www.york.ac.uk/satsu/remedie
26. Flemming A. Pfizer and GSK join race for T cell cancer therapies. Nat. Rev. Drug Discov. 13(8), 568-569 (2014)
27. Bryant LM, Christopher DM, Giles AR et al. Lessons learned from the clinical Development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev. 24(2), 55-64 (2013)
28. Fierce Pharma. www.fiercepharma.com 29 Reuters. http://uk.reuters.com